Gastric polyps' regression after potassium‐competitive acid blocker cessation [PDF]
Journal of General and Family Medicine, 2022 Esophagogastroduodenoscopic examination shows a large, reddish polyp in the gastric cardia. The polyp decreased in size at 10 months and 22 months after cessation of vonoprazan.
Masaya Iwamuro +2 more
doaj +4 more sources
Potassium-competitive acid blocker-associated gastric mucosal lesions [PDF]
Clinical EndoscopySince the introduction of vonoprazan, a potassium-competitive acid blocker (P-CAB), it has been demonstrated to reversibly inhibit gastric acid secretion by engaging in potassium-competitive ionic binding to H+/K+-ATPase.
Kimitoshi Kubo +2 more
doaj +4 more sources
Vonoprazan: A New Potassium-Competitive Acid Blocker. [PDF]
J Pharm Technol, 2023 Objective: To review the safety, efficacy, and tolerability of vonoprazan for the treatment of Helicobacter pylori infection in adults. Data Sources: A literature search was performed through PubMed using the following key terms: vonoprazan, Voquezna, TAK-438, potassium-competitive acid blocker, H pylori, and gastrointestinal. Study Selection and Data
St Onge E, Phillips B.
europepmc +5 more sources
Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function [PDF]
Frontiers in Immunology, 2022 Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder characterized by prolonged inflammation of the gastrointestinal tract. IBD can result from gut barrier dysfunction, altered gut microbiota, and abnormal intestinal immunity induced by
Mijeong Son +11 more
doaj +4 more sources
Vonoprazan a novel potassium competitive acid blocker; another leap forward [PDF]
Gastroenterology ReviewThe eradication rate of Helicobacter pylori (H. pylori) has decreased due to antibiotics resistance and inadequate acid suppression. Vonoprazan is a novel potassium-competitive acid blocker (P-CAB), which has a rapid and sustained acid inhibitory effect and may be more effective than conventional proton pump inhibitors (PPIs) in H.
Maha Elsabaawy +5 more
doaj +4 more sources
Proton pump inhibitor versus potassium‐competitive acid blocker in gastroesophageal reflux disease [PDF]
JGH OpenTadayuki Oshima
doaj +4 more sources
Pharmacological characterization of linaprazan glurate (X842), a novel potassium-competitive acid blocker, in vitro and in vivo [PDF]
Frontiers in PharmacologyIntroductionThe aim of this study is to characterize the pharmacology of linaprazan glurate (X842), an ethyl ester prodrug of linaprazan (a novel potassium-competitive acid blocker), in animal species in vitro and in vivo to achieve a better ...
Ming Lu +9 more
doaj +2 more sources
Role of Potassium-Competitive Acid Blockers in Helicobacter pylori Eradication [PDF]
The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2017 The first-line therapy for Helicobacter pylori infection comprises triple therapy with the combination of a proton pump inhibitor (PPI), amoxicillin, and clarithromycin. However, the H.
Jong Kyu Park
doaj +2 more sources
Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial [PDF]
Gut and Liver, 2022 Background/Aims: We examined the efficacy and safety of tegoprazan as a part of first-line triple therapy for Helicobacter pylori eradication. Methods: A randomized, double-blind, controlled, multicenter study was performed to evaluate whether tegoprazan
Yoon Jin Choi +20 more
doaj +2 more sources
Optimal Use of Proton Pump Inhibitors and Potassium-competitive Acid Blockers [PDF]
The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2023 A variety of proton pump inhibitors (PPIs) have been developed in Korea since the introduction of omeprazole (the first PPI) in 1989. PPIs have served as the basic therapeutic approach for the management of gastric acid-related diseases for 30 years and ...
Jong Kyu Park
doaj +2 more sources